Skip to content

Study · In vitro (cells) · 2016

2 results

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.

Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ

Endocrinology12 Nov 2015Cited by 231 (Europe PMC)

PMID26562265 (opens in a new tab)PMCIDPMC4701881 (opens in a new tab)DOI10.1210/en.2015-1726 (opens in a new tab)PepBankPUB-26562265
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In laboratory receptor studies, abaloparatide bound more selectively to the RG conformation than PTH (1-34).

    In plain wordsIn lab tests, abaloparatide bound more selectively to the RG receptor conformation than PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseRG receptor conformation selectivity
    Study

    n: not reported in source

    PTHR1-expressing cells
    Comparator
    PTH (1-34)
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We show that ABL indeed binds with greater selectivity to the RG conformation than does PTH (1-34), and as a result of this RG bias, ABL mediates more transient cAMP responses in PTHR1-expressing cells.
  2. 02LabIn vitro (cells)Mechanism

    In PTHR1-expressing cells, abaloparatide produced more transient cAMP responses than PTH (1-34) through RG-biased binding.

    In plain wordsIn cells, abaloparatide produced shorter cAMP responses than PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreasecAMP response duration
    Study

    n: not reported in source

    PTHR1-expressing cells
    Comparator
    PTH (1-34)
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We show that ABL indeed binds with greater selectivity to the RG conformation than does PTH (1-34), and as a result of this RG bias, ABL mediates more transient cAMP responses in PTHR1-expressing cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03710889

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Radius Health, Inc.n = 2320 Sept 2018 to 15 Jul 2020

Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral · Osteoporosis Risk · Osteoporosis Fracture · Osteoporosis Localized to Spine · Osteoporosis, Age-Related · Osteoporosis Senile · Osteoporosis of Vertebrae

Trial pageClinicalTrials.govUpdated 15 Oct 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.